Boehringer Ingelheim and BioMed X collaborate to discover new epigenetic regulators of COPD
BioMed X announced that they have entered into a collaboration agreement with Boehringer Ingelheim to establish a research group focusing on the identification of novel therapeutic concepts for treating patients with chronic obstructive pulmonary disease (COPD).
Outstanding early career scientists from leading academic institutions world-wide are invited to submit original project proposals in the field of epigenetics and COPD. Boehringer Ingelheim and BioMed X will jointly select the best ideas and life science talents to form a new research group within BioMed X's open innovation lab in Heidelberg.
BioMed X will be responsible for recruitment of the new research group, the operation of the innovation center facility, providing entrepreneurial education and enabling access to the Heidelberg scientific community and research facilities. "We welcome Boehringer Ingelheim as additional pharmaceutical partner to our Innovation Center", said Christian Tidona, founder and Managing Director of BioMed X. "This is a major milestone in our endeavor to bridge the translational gap between academia and the pharmaceutical industry."
Further details of the agreement and financial terms are not disclosed.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.